Blind Clinical Study of NuGene’s Light and Bright Gel(TM) Shows 89% of Participants Experience a 50% or More Improvement in Their Hyperpigmentation Appearance
IRVINE, CA–(Marketwired – Sep 29, 2015) – NuGene International, Inc. (“NuGene”) (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, was recently featured in a study and presentation by Dr. Dendy Engelman, a NuGene Advisory Board member and Director of Dermatological Surgery at New York Medical College. The presentation of the results occurred at the 6th Five-Continent Congress on Lasers and Aesthetic Medicine held September 3-6 in Cannes, France.
Dr. Engelman’s presentation titled, Potent Human Adipose Derived Stem Cell Treatments Revolutionizing Topical Anti-Aging Therapy, described a limited study performed to assess the efficacy of NuGene’s Light and Bright Gel in improving the appearance of skin pigmentation. In the study, blinded investigators observed an improvement in skin pigmentation appearance with all patients where:
•33% of patients experienced a 50% improvement in skin appearance
•56% of patients experienced a 75% improvement in skin appearance
The subjects of the study were females between the ages of 30 to 60 years old, with hyperpigmentation on the face with moderate severity. The products used in the study featured NuGene’s unique stem cell based technology employing a high concentration of bioactive molecules from stem cell culture media derived from human adipose stem cells.
In the study, the information was collected by an independent investigator who was provided with photographic evidence showing before and after images of the participants and concluded that there was significant improvement in the lack of the appearance of aging. Images of participants before and after the use of the product can be viewed here.
“NuGene’s Light and Bright Gel provides an innovative approach to skin and hair rejuvenation. Clinical findings from topical application of NuGene’s product yielded results, in my opinion, previously only attainable by in-office procedures. I have been overwhelmed by the efficacy of this product and am thrilled to offer this product line to my patients,” remarked Dr. Engelman.
“Dr. Engelman presented NuGene’s non-hydroquinone based solution for hyperpigmentation aesthetics to some of the world’s top dermatologists and aestheticians. NuGene has a significant opportunity to impact this expanding market,” said Dr. Saeed Kharazmi, Chairman and co-founder of NuGene. Hydroquinone, a common component of bleaching creams, has already been banned in Japan, the European Union, and Australia due to potential cancer concerns.
About Dr. Dendy Engelman
Dr. Engelman is a board certified dermatologic surgeon and an associate at Manhattan Dermatology & Cosmetic Surgery. She is a fellow of the American Academy of Dermatology, American Society of Dermatologic Surgery and American College of Mohs Surgery (a procedure that removes skin cancer under local anesthetic). Most recently, Dr. Engelman was appointed Director of Dermatologic Surgery at New York Medical College where she oversees the training of future Mohs surgeons and dermatologists. Dr. Engelman also serves as a scientific advisory board member of NuGene and consultant to numerous pharmaceutical companies including Genetech, Allergen, Galderma, Merz and L’Oreal.
About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the “next evolution of medical treatments.” The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Service Global Cosmeceuticals Market report. NuGene’s cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene’s exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications. NuGene’s goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.
Forward Looking Statements
This document contains “forward-looking statements: statements related to future, not past, events. In this context, forward-looking statements often address NuGene’s expected future business and financial performance and financial condition, and often contain words such as “expect: “anticipate,” intend,” plan,” “believer,” “seek,” “see,” “will,” “would,” or “target.”
Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about our current and future sales, planned operations, marketing activities and other operational, sales and financial plans. These may include our ability to convert pre-order commitments/wins into orders; timing of planned and anticipated product deliveries; the price we realize on orders since commitments/wins are stated at list prices; customer actions or developments such as customer returns and other factors that may affect the level of demand and performance of the major industries and customers we serve; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of regulation and litigation; adverse market conditions, timing of and ability to obtain required regulatory approvals, or other factors relating to us; the impact of potential information technology or data security breaches; and the other factors. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.
Investor/ Media Relations: